James J. Loughlin

Filings by James J. Loughlin span 5 companies, the busiest being Celgene Corp /DE/, PDS Biotechnology Corp and InspireMD, Inc. Over a trading history stretching from 25 July 2006 to 20 November 2019, the count stands at 66 filings.

On the open market, the record shows 15 purchases worth €222k and 9 sales worth €11.3M. The net balance comes to €11.1M on the selling side. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Outside the open market, there are 1 share grant and 36 option exercises. So far in 2019, the count stands at no purchases and 1 sale.

The median purchase comes to €6,868. 8 out of 9 purchases came within 30 days of a purchase by at least one other insider of the same company. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase. After 9 purchases with a full 90-day history, the hit rate stands at 89% and the median 90-day move at +13.8%. Past outcomes like these are no guarantee of what comes next.

On 22 November 2019 came the latest disclosure, a transaction in Celgene Corp /DE/. The latest purchase dates back some time: it was published 3,521 days ago, on 7 March 2017. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. For comparison, the SEC allows two business days to file a Form 4. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.